NK Cell Therapy After Stem Cell Transplant for Childhood Leukemia or Neuroblastoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immunotherapy using natural killer cells (immune cells that fight cancer) given after a stem cell transplant in children with leukemia or neuroblastoma. The goal is to see if these cells help prevent cancer from coming back and are safe for young patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must be between 2 and 13 years old
- Diagnosed with acute leukemia or neuroblastoma
- Had an allogeneic stem cell transplant (donor cells) between 30 and 90 days before starting the trial
- Blood NK cell count of at least 100 million cells per liter at some point before the trial
- Expected to live at least 3 more months based on doctor's judgment
- Not currently taking high-dose steroids (prednisone equivalent) or cyclosporine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This trial tests a new type of immune cell called natural killer (NK) cells from healthy donors to treat neuroblastoma that has not responded to standard treatments. The goal is to see if these cells can help shrink or control the cancer.
This trial tests a new natural killer (NK) cell therapy for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy targets two specific markers (CLL1 or CD33) on leukemia cells. It aims to see if these immune cells can safely fight the cancer.
This trial tests a new type of immune cell therapy (NK cells) for patients with malignant brain tumors that have come back or worsened despite previous treatment. The goal is to see if these specially prepared immune cells can help fight the cancer.
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.